Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. [electronic resource]
Producer: 20170626Description: 795-805 p. digitalISSN:- 1941-837X
- 2-Naphthylamine
- Adult
- Aged
- Aged, 80 and over
- Anilides -- economics
- Antiviral Agents -- administration & dosage
- Benzimidazoles -- economics
- Carbamates -- economics
- Carcinoma, Hepatocellular -- economics
- Cost-Benefit Analysis
- Cyclopropanes
- Drug Therapy, Combination
- Female
- Fibrosis -- economics
- Fluorenes -- economics
- Genotype
- Hepacivirus -- genetics
- Hepatitis C, Chronic -- drug therapy
- Humans
- Lactams, Macrocyclic
- Liver Neoplasms -- economics
- Macrocyclic Compounds -- economics
- Male
- Markov Chains
- Middle Aged
- Models, Econometric
- Proline -- analogs & derivatives
- Quality-Adjusted Life Years
- Ribavirin -- economics
- Simeprevir
- Sofosbuvir -- economics
- Sulfonamides -- economics
- Uracil -- analogs & derivatives
- Valine
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.